Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Normalized Income after Taxes of $-35.04M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-35.04M |
|
-- |
|
-- |
|
$36.19M |
|
$-36.19M |
|
$1.15M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
|
Normalized Income after Taxes |
$-35.04M |
$-36.19M |
|
$-36.37M |
|
19.41M |
|
19.41M |
|
$-1.81 |
|
$-1.81 |
|
| Balance Sheet Financials | |
$122.75M |
|
$0.07M |
|
$4.24M |
|
$126.99M |
|
$21.48M |
|
-- |
|
$3.27M |
|
$24.75M |
|
$102.24M |
|
$102.24M |
|
$102.24M |
|
18.67M |
|
| Cash Flow Statement Financials | |
$-55.20M |
|
$40.72M |
|
$9.07M |
|
$29.16M |
|
$23.75M |
|
$-5.41M |
|
$3.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-55.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.27% |
|
-34.27% |
|
-27.59% |
|
-34.27% |
|
$5.48 |
|
$-2.84 |
|
$-2.84 |
|